期刊
BIOMOLECULES
卷 12, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/biom12010054
关键词
ubiquitin-proteasome system; immunoproteasome
资金
- NIH [RO1CA213223]
Proteasome is a crucial protein degradation machine in maintaining protein homeostasis and regulating cell functions. FDA-approved proteasome inhibitors are used for multiple myeloma treatment. Various inhibitors target different active sites of the proteasome, impacting its biological functions and identifying potential drug targets for disease treatment.
Proteasome is a multi-subunit protein degradation machine, which plays a key role in the maintenance of protein homeostasis and, through degradation of regulatory proteins, in the regulation of numerous cell functions. Proteasome inhibitors are essential tools for biomedical research. Three proteasome inhibitors, bortezomib, carfilzomib, and ixazomib are approved by the FDA for the treatment of multiple myeloma; another inhibitor, marizomib, is undergoing clinical trials. The proteolytic core of the proteasome has three pairs of active sites, beta 5, beta 2, and beta 1. All clinical inhibitors and inhibitors that are widely used as research tools (e.g., epoxomicin, MG-132) inhibit multiple active sites and have been extensively reviewed in the past. In the past decade, highly specific inhibitors of individual active sites and the distinct active sites of the lymphoid tissue-specific immunoproteasome have been developed. Here, we provide a comprehensive review of these site-specific inhibitors of mammalian proteasomes and describe their utilization in the studies of the biology of the active sites and their roles as drug targets for the treatment of different diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据